Optimum Video Q&A: Getting to know Renee Aguiar-Lucander

Since taking over as CEO of Calliditas Therapeutics in 2017, Renee Aguiar-Lucander has taken the biotech through an IPO in Stockholm and commenced a pivotal phase 3 trial plus major licensing deals and a secondary fund raise.  She has established a US presence, made transformational regulatory milestones, and this month completed a successful upsized US listing on NASDAQ raising USD 90 million. Eleanor Malone, Editor SCRIP Intelligence speaks to Renee about her experiences.

Check out interview HIGHLIGHTS or watch full interview below.

 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH